D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review
Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.
Pharma & Biotech